Navigation Links
Quintessence cancer treatment chosen for clinical studies

Madison, Wis. - Quintessence Biosciences, a biopharmaceutical company developing cancer therapies, has announced that QB139, one of its EVade cancer treatments, has been selected for preclinical testing and human clinical trials.

Quintessence said that pending a favorable preclinical safety assessment, it would submit to the

Source:wistechnology.com By WTN News 11/09/06


Page: 1

Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence division to develop drug tests with NIH grant
4. Quintessence Biosciences forms cancer therapeutic advisory board
5. Quintessence Secures Financing
6. NeoClone gets $750K for ovarian cancer detection
7. Medical College receives $1.4M cancer grant
8. GE Healthcare partners with UNC on breast cancer imaging research
9. Lance Armstrong and the future of cancer care
10. Medical College part of $5M cancer study
11. UW finds new path to anti-cancer agents
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/1/2017)... , March 1, 2017  Trovagene, Inc. (NASDAQ: TROV), ... today that it will report financial results for the fourth ... 15, 2017. Trovagene,s senior management team will host ... p.m. Eastern Daylight Time (2:00 p.m. Pacific Daylight Time) to ... ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017  Luxcel ... based Biotechnology Company and HD Biosciences Co., ... Research Organization (CRO), announced today that they have ... new assay technologies for preclinical drug safety services. ... Luxcel,s state-of-the-art assays and technologies for assessment of ...
(Date:3/1/2017)... Conn. (PRWEB) , ... March 01, 2017 , ... ... Group, Inc. will hold its annual technology show and open house, Southern Tech ... CNC machinery from Okuma, Tsugami, Hardinge Group and Chiron and perform live metal ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... Inc. (Newark, DE) have formed a strategic partnership to develop and market ... renewable energy laboratories. These automated testing solutions will save analysis time and ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
Breaking Biology News(10 mins):